Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 13, 2025
Daily News
June 13, 2025
- MHLW Panel OKs Report on Clinical Trials, Calls for Model Project on FMV Cost Approach
June 13, 2025
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Japan Vaccine Market to Reach 297 Billion Yen in FY2025: Fuji Keizai
June 13, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- Nippon Chemiphar to Launch Amaryl AGs on June 20
June 13, 2025
- Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…